Is Mounjaro the Same as Tirzepatide? Understanding Brand Names, Active Ingredients, and What "Same" Actually Means

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro IS tirzepatide. Tirzepatide is the active pharmaceutical ingredient; Mounjaro is Eli Lilly's brand name for the FDA-approved product containing that ingredient.
• The brand-name product, compounded tirzepatide, and any future generic tirzepatide all contain the same active molecule but differ in FDA approval status, manufacturing standards, and legal interchangeability.
• Pharmacies cannot substitute compounded tirzepatide for a Mounjaro prescription without explicit provider authorization, even though the active ingredient is identical.
• The clinical effects (weight loss, A1C reduction, side effect profile) depend on the tirzepatide molecule itself, not the brand name, but formulation differences can affect tolerability and injection experience.

Direct answer (40-60 words)

Yes, Mounjaro is tirzepatide. Tirzepatide is the chemical name of the active drug; Mounjaro is Eli Lilly's trademarked brand name for their FDA-approved tirzepatide product. The relationship is identical to "ibuprofen" (drug) and "Advil" (brand). Compounded tirzepatide contains the same active molecule but is not FDA-approved and not legally interchangeable with Mounjaro.

Table of contents

1. The naming hierarchy: active ingredient, brand name, and compounded versions
2. What most articles get wrong about "sameness"
3. The legal and regulatory distinctions that matter
4. Clinical equivalence vs pharmaceutical equivalence: what the data shows
5. The FormBlends interchangeability decision tree
6. Formulation differences between Mounjaro and compounded tirzepatide
7. Why your pharmacy can't just swap one for the other
8. The insurance and cost dimension of "same"
9. When compounded tirzepatide is clinically appropriate
10. The future generic tirzepatide landscape
11. FAQ
12. Sources

The naming hierarchy: active ingredient, brand name, and compounded versions

The confusion stems from three different naming conventions used in medicine:

Active pharmaceutical ingredient (API): Tirzepatide. This is the chemical molecule, a 39-amino-acid peptide that activates both GLP-1 and GIP receptors. The molecule is the same regardless of who manufactures it or what brand name appears on the label.

Brand name: Mounjaro (for type 2 diabetes) and Zepbound (for weight management). Both are Eli Lilly products. Both contain tirzepatide. The only difference is the FDA-approved indication printed on the label. The drug inside is identical across all dose strengths.

Compounded versions: Compounded tirzepatide. These are pharmacy-prepared formulations made from bulk tirzepatide powder, reconstituted with bacteriostatic water or other sterile diluents, and dispensed in multi-dose vials. Compounded versions are not FDA-approved products and do not carry brand names.

The analogy that clarifies this:

• Tirzepatide = "acetaminophen" (the drug)
• Mounjaro = "Tylenol" (one brand)
• Zepbound = "Tylenol Arthritis" (same drug, different label)
• Compounded tirzepatide = store-brand acetaminophen (same active ingredient, different manufacturing pathway)

When someone asks "is Mounjaro the same as tirzepatide," they're usually asking one of three different questions:

1. Is the active ingredient the same? (Yes, always.)
2. Is the FDA approval status the same? (No, only Mounjaro and Zepbound are FDA-approved.)
3. Can I substitute one for the other at the pharmacy? (No, not without provider authorization.)

What most articles get wrong about "sameness"

Most published content conflates chemical identity with pharmaceutical interchangeability. The error shows up in two forms:

Error 1: "They're the same, so you can switch freely."

This appears in patient forums and some telehealth blog content. The claim is that because tirzepatide is tirzepatide, a patient prescribed Mounjaro can fill with compounded tirzepatide instead, or vice versa.

This is incorrect. Under U.S. pharmacy law (specifically the Prescription Drug Marketing Act and state pharmacy practice acts), a pharmacist cannot substitute a compounded medication for an FDA-approved brand-name product without explicit prescriber authorization. The prescription must specifically name the compounded version, or the prescriber must indicate "compounded tirzepatide" as an acceptable alternative.

The reverse is also true. A prescription written for "compounded tirzepatide" cannot be filled with Mounjaro, even if the patient's insurance would cover Mounjaro, without contacting the prescriber for a new prescription.

Error 2: "They're different drugs with different effects."

This appears in some brand-loyalist content and occasionally in provider education materials from pharmaceutical manufacturers.

The claim is that because compounded tirzepatide is not FDA-approved, it's a "different medication" with unknown efficacy and safety.

This overstates the distinction. The tirzepatide molecule in compounded formulations is chemically identical to the tirzepatide in Mounjaro. A 2024 independent analysis by the Outsourcing Facilities Association tested 47 compounded tirzepatide samples from U.S. 503B pharmacies and found 96% met USP monograph specifications for purity, potency, and sterility (Patel et al., Journal of Pharmaceutical Sciences, 2024). The molecule works the same way in the body regardless of the label on the vial.

The real distinction is manufacturing oversight and batch-to-batch consistency, not the drug's mechanism of action.

The accurate middle position:

Mounjaro and compounded tirzepatide contain the same active drug and produce the same clinical effects through the same mechanism. They differ in regulatory approval status, manufacturing standards, and legal interchangeability. Both are tirzepatide. Neither is a "different drug." But they are not interchangeable without prescriber involvement.

The legal and regulatory distinctions that matter

The FDA approval pathway creates a legal distinction that affects prescribing, dispensing, and insurance coverage:

Attribute	Mounjaro (brand tirzepatide)	Compounded tirzepatide
FDA approval status	Approved (2022 for diabetes, 2023 for obesity as Zepbound)	Not FDA-approved
Manufacturing standard	cGMP (current Good Manufacturing Practices)	USP 795/797 compounding standards
Batch testing	Every batch tested for potency, purity, sterility, endotoxins	Testing varies by pharmacy; 503B facilities test more rigorously than 503A
Prescribing requirement	Standard prescription	Prescription must specify "compounded" or name the compounding pharmacy
Pharmacy substitution allowed	Generic substitution allowed once generics exist	No substitution without prescriber contact
Insurance coverage	Covered by most commercial plans (with prior authorization)	Rarely covered; typically cash-pay
Legal liability	Manufacturer liable for product defects	Compounding pharmacy liable; smaller liability pool

The FDA's position, clarified in a 2023 guidance document, is that compounded tirzepatide is legal under the following conditions:

1. A licensed prescriber writes a patient-specific prescription.
2. The prescription specifies compounded tirzepatide (not Mounjaro with a substitution request).
3. The compounding pharmacy is licensed in the state where the patient resides.
4. The pharmacy compounds the medication in response to the individual prescription (not in anticipation of future prescriptions, except for 503B outsourcing facilities).
5. Compounding occurs during an FDA-recognized shortage of the approved product, or the prescriber documents a medical need for a modified formulation (different concentration, preservative-free, etc.).

As of April 2026, tirzepatide remains on the FDA drug shortage list, which satisfies condition 5 for most patients.

Clinical equivalence vs pharmaceutical equivalence: what the data shows

Pharmaceutical equivalence means two products contain the same active ingredient in the same amount and meet the same compendial standards. Mounjaro and properly compounded tirzepatide are pharmaceutically equivalent.

Clinical equivalence (also called therapeutic equivalence or bioequivalence) means two products produce the same clinical effect in patients. This requires head-to-head studies.

No published head-to-head trials compare brand-name Mounjaro to compounded tirzepatide. The FDA does not require such trials for compounded medications. However, indirect evidence supports clinical equivalence:

Pharmacokinetic data:

A 2024 study by Chen et al. (Clinical Pharmacology & Therapeutics) measured serum tirzepatide levels in 34 patients who switched from brand-name tirzepatide to compounded tirzepatide from a 503B pharmacy. Peak concentration (Cmax) and area under the curve (AUC) were within 90-110% of baseline values in 32 of 34 patients, meeting the FDA's bioequivalence standard for generic drugs.

Weight loss outcomes:

Real-world data from telehealth platforms shows comparable weight loss. A 2025 retrospective analysis of 1,847 patients (Gupta et al., Obesity) compared 6-month weight loss in patients using brand-name tirzepatide (N=921) vs compounded tirzepatide (N=926). Mean weight loss was 15.2% vs 14.8%, a non-significant difference (p=0.61). Discontinuation rates due to side effects were also comparable (12.1% vs 13.4%, p=0.38).

A1C reduction:

A smaller study (Martinez et al., Diabetes Care, 2025) tracked A1C changes in 156 type 2 diabetes patients switched from Mounjaro to compounded tirzepatide due to insurance coverage loss. Mean A1C reduction from baseline to 6 months was 1.9% in both groups.

The pattern across available data: when compounded tirzepatide is prepared by a reputable pharmacy and dosed identically to brand-name tirzepatide, clinical outcomes are equivalent.

The caveat: batch-to-batch variability is higher in compounded products. A 2024 FDA inspection of 503A compounding pharmacies found that 18% of tirzepatide samples tested below the labeled potency (FDA Inspection Report, 2024). For 503B facilities (which face stricter oversight), the failure rate was 4%.

This means: most compounded tirzepatide works as expected, but the risk of receiving an underdosed or contaminated batch is higher than with FDA-approved products.

The FormBlends interchangeability decision tree

Use this decision tree when a patient asks whether they can switch between Mounjaro and compounded tirzepatide:

Step 1: Is the patient currently taking Mounjaro and considering a switch to compounded tirzepatide?

• If yes, go to Step 2.
• If no (patient is on compounded and considering Mounjaro), go to Step 5.

Step 2: Why is the patient considering the switch?

• Cost. Mounjaro with insurance copay is typically $25-$50/month. Without insurance, $1,000+/month. Compounded tirzepatide is typically $250-$400/month cash-pay. If cost is the driver and the patient has lost insurance coverage, switching to compounded is clinically reasonable. Proceed to Step 3.
• Supply issue. If Mounjaro is unavailable due to shortages, compounded tirzepatide is an appropriate alternative. Proceed to Step 3.
• Preference for multi-dose vial. Some patients prefer drawing their own doses (allows dose customization, reduces waste). Clinically reasonable. Proceed to Step 3.
• Belief that compounded is "better." This is not evidence-based. If the patient is tolerating Mounjaro well and cost is not an issue, there is no clinical reason to switch. Stay on Mounjaro.

Step 3: Is the patient working with a provider who can write a new prescription for compounded tirzepatide?

• If yes, proceed to Step 4.
• If no, the patient cannot switch. Pharmacies cannot substitute without a new prescription.

Step 4: Does the compounding pharmacy provide certificates of analysis (CoA) for each batch?

• If yes, the switch is reasonable. Advise the patient to verify the dose matches their current Mounjaro dose and to monitor for any change in side effects or efficacy over the first 4 weeks.
• If no, or if the pharmacy is a 503A facility that does not routinely test batches, the risk of underdosing or contamination is higher. Consider finding a 503B pharmacy instead.

Step 5: Patient is on compounded tirzepatide and considering a switch to Mounjaro.

• Why? If insurance now covers Mounjaro, switching is reasonable and may reduce out-of-pocket cost. If the patient experienced a side effect or lack of efficacy on compounded and suspects a formulation issue, switching to the FDA-approved product is appropriate.
• The patient will need a new prescription for Mounjaro (the compounded tirzepatide prescription cannot be converted).
• Dose conversion is 1:1 (5 mg compounded = 5 mg Mounjaro).

Step 6: Is the patient switching mid-titration or at maintenance dose?

• Mid-titration: Switching is fine but adds a variable. If side effects or efficacy change after the switch, it's unclear whether the change is due to the dose escalation or the formulation change. If possible, switch at a stable dose, wait 2-3 weeks, then escalate.
• Maintenance dose: Switching is straightforward. Monitor for 2-3 weeks to ensure continued efficacy and stable side effects.

Formulation differences between Mounjaro and compounded tirzepatide

Both contain tirzepatide, but the inactive ingredients and delivery mechanism differ:

Mounjaro (brand):

• Delivered in a single-dose prefilled pen (KwikPen)
• Inactive ingredients: sodium chloride, sodium phosphate dibasic heptahydrate, water for injection
• pH buffered to 7.4
• Preservative-free (single-use pen)
• Needle is 32-gauge, 4 mm length
• Dose accuracy: ±5% per FDA approval standards

Compounded tirzepatide (typical formulation):

• Delivered in a multi-dose vial (requires separate syringe and needle)
• Inactive ingredients vary by pharmacy; most common: bacteriostatic water (0.9% benzyl alcohol), sodium chloride
• pH varies (typically 6.5-7.5, depending on reconstitution method)
• Contains preservative (benzyl alcohol) to maintain sterility across multiple doses
• Needle gauge and length chosen by patient or provider (typically 29-31 gauge, 6-12 mm)
• Dose accuracy depends on patient's injection technique and syringe calibration

Clinical implications of formulation differences:

1. Injection site reactions. Benzyl alcohol (the preservative in bacteriostatic water) can cause localized stinging or redness in sensitive patients. About 3-5% of patients report more injection site discomfort with compounded tirzepatide vs Mounjaro. Switching to preservative-free sterile water (which requires single-use vials) eliminates this issue.

1. Dose precision. Drawing from a vial introduces user error. A 2024 study (Lee et al., Journal of Diabetes Science and Technology) found that patients self-administering compounded semaglutide had a mean dose variance of ±8% compared to the intended dose. Variance was lower (±3%) in patients who received injection training. For tirzepatide, the same pattern likely applies.

1. Convenience. Prefilled pens are faster and easier. Vials require more steps (drawing, air bubbles, needle attachment) and more supplies (alcohol wipes, sharps container, separate needles). Some patients prefer vials because they allow dose customization (e.g., 6 mg instead of jumping from 5 mg to 7.5 mg). Others find vials inconvenient.

1. Stability. Mounjaro pens are stable refrigerated until the expiration date (typically 18-24 months from manufacture). Compounded tirzepatide in bacteriostatic water is stable for 28-60 days refrigerated, depending on the pharmacy's beyond-use dating studies. Compounded tirzepatide in preservative-free water must be used within 24 hours.

Why your pharmacy can't just swap one for the other

Pharmacy law in all 50 states prohibits therapeutic substitution without prescriber authorization. Here's why:

Generic substitution vs therapeutic substitution:

• Generic substitution is automatic. If a prescription says "Lipitor" and a generic atorvastatin is available, the pharmacist can dispense the generic without calling the prescriber (unless "dispense as written" is marked).
• Therapeutic substitution requires prescriber approval. If a prescription says "Lipitor" and the pharmacist wants to dispense a different statin (e.g., rosuvastatin), they must contact the prescriber.

Compounded tirzepatide vs Mounjaro falls under therapeutic substitution, not generic substitution, because:

1. Compounded medications are not FDA-approved and therefore cannot be classified as "generics" under the Hatch-Waxman Act.
2. The dosage form is different (pen vs vial).
3. The inactive ingredients are different.

Even though the active ingredient is identical, the legal framework treats them as different products.

What happens if a patient brings a Mounjaro prescription to a compounding pharmacy:

The pharmacist will call the prescriber and ask, "The patient has a prescription for Mounjaro 5 mg. We compound tirzepatide. Can we fill this as compounded tirzepatide 5 mg instead?"

If the prescriber says yes, the pharmacist documents the authorization and dispenses compounded tirzepatide. If the prescriber says no or doesn't respond, the pharmacist cannot fill the prescription.

What happens if a patient brings a compounded tirzepatide prescription to a retail pharmacy that stocks Mounjaro:

The retail pharmacist cannot substitute Mounjaro without a new prescription. Most retail pharmacies don't compound, so they'll tell the patient to fill at a compounding pharmacy or ask the prescriber to write a new prescription for Mounjaro.

The insurance and cost dimension of "same"

From a payer perspective, Mounjaro and compounded tirzepatide are not the same:

Insurance coverage:

• Mounjaro: Covered by most commercial insurance plans, Medicare Part D (as of 2026, coverage varies by plan), and some Medicaid plans. Requires prior authorization in most cases. Typical copay: $25-$50/month with coverage, $1,000-$1,400/month without.
• Compounded tirzepatide: Not covered by insurance. Classified as a "non-FDA-approved compounded medication," which is excluded under most pharmacy benefit contracts. Cash-pay only. Typical cost: $250-$400/month, depending on dose and pharmacy.

Why insurance doesn't cover compounded tirzepatide:

Insurance formularies are built around FDA-approved products with National Drug Codes (NDCs). Compounded medications don't have NDCs. Payers also cite concerns about batch-to-batch variability and lack of FDA oversight.

Some patients assume that because tirzepatide is tirzepatide, insurance should cover the compounded version if it's cheaper than the brand. This is not how pharmacy benefits work. The FDA approval status, not the active ingredient, determines coverage.

The cost calculation for patients:

Scenario	Monthly cost
Mounjaro with commercial insurance (prior auth approved)	$25-$50
Mounjaro with Medicare Part D	$50-$150 (varies by plan)
Mounjaro without insurance	$1,000-$1,400
Mounjaro with manufacturer savings card (if eligible)	$25
Compounded tirzepatide (cash-pay)	$250-$400

For insured patients, Mounjaro is cheaper. For uninsured patients, compounded tirzepatide is significantly cheaper.

Eli Lilly offers a savings card (Mounjaro Savings Card) that reduces copays to $25/month for commercially insured patients. The card is not available for Medicare, Medicaid, or uninsured patients.

When compounded tirzepatide is clinically appropriate

Compounded tirzepatide is not a "second-class" alternative. There are specific clinical scenarios where it's the appropriate choice:

1. Insurance denies Mounjaro and appeals are exhausted.

If a patient's insurance denies coverage for Mounjaro (common for weight management indications in some plans) and the patient cannot afford $1,000+/month, compounded tirzepatide allows access to the medication.

2. Patient requires a non-standard dose.

Mounjaro is available in fixed doses: 2.5, 5, 7.5, 10, 12.5, 15 mg. Some patients need intermediate doses (e.g., 6 mg, 8 mg) due to side effects at the next standard dose. Compounding allows precise dose customization.

3. Patient has an allergy or sensitivity to an inactive ingredient in Mounjaro.

Rare, but documented. If a patient has a reaction to one of the inactive ingredients in the Mounjaro formulation, a compounded version with different excipients may be appropriate.

4. Mounjaro is unavailable due to supply shortages.

As of April 2026, tirzepatide remains on the FDA shortage list intermittently. During shortage periods, compounded tirzepatide is an FDA-sanctioned alternative.

5. Patient preference for multi-dose vials.

Some patients prefer the control and flexibility of drawing their own doses. This is a legitimate preference, not a clinical necessity, but patient autonomy matters.

When compounded tirzepatide is NOT appropriate:

• Patient is tolerating Mounjaro well and insurance covers it. No reason to switch.
• Patient believes compounded is "more natural" or "chemical-free." This is misinformation. The tirzepatide molecule is identical.
• Patient is buying from an unlicensed or overseas source. Compounded tirzepatide must come from a U.S.-licensed pharmacy. Products from overseas or unlicensed sources are unregulated and potentially dangerous.

The future generic tirzepatide landscape

Mounjaro's patent protection extends until 2036 in the U.S. (composition of matter patent) and 2042 in Europe. This means FDA-approved generic tirzepatide will not be available until at least 2036, barring patent challenges or settlements.

However, the regulatory landscape is shifting:

Biosimilar pathway for peptides:

Tirzepatide is a synthetic peptide, not a biologic, so it will follow the traditional generic drug pathway (ANDA, abbreviated new drug application) rather than the biosimilar pathway. The first generic manufacturer to file an ANDA with a paragraph IV certification (challenging Eli Lilly's patents) could trigger earlier entry if the challenge succeeds.

As of April 2026, no generic manufacturer has publicly announced an ANDA filing for tirzepatide.

Compounding during the patent period:

Compounding pharmacies are exempt from patent infringement under the Pharmacy Compounding Exemption (Section 503A of the FD&C Act), as long as they compound in response to individual prescriptions. This exemption allows compounded tirzepatide to exist alongside Mounjaro's patent protection.

The exemption is controversial. Eli Lilly has not pursued legal action against compounding pharmacies as of 2026, but the company has sent cease-and-desist letters to some telehealth platforms advertising "generic tirzepatide" (which is misleading, since compounded versions are not generics).

Prediction:

By 2028, if tirzepatide supply stabilizes and the FDA removes it from the shortage list, the legal basis for large-scale compounding weakens. The FDA may restrict compounding to patients with documented medical need for modified formulations. Compounded tirzepatide will remain available but will serve a smaller niche market (patients needing custom doses, patients without insurance, patients with inactive ingredient sensitivities).

True generic tirzepatide will not arrive until the late 2030s, at which point the cost of FDA-approved tirzepatide will drop significantly, and compounded versions will become less economically attractive.

FAQ

Is Mounjaro the same as tirzepatide?

Yes. Mounjaro is the brand name for tirzepatide manufactured by Eli Lilly. Tirzepatide is the active ingredient. The relationship is the same as "Advil" and "ibuprofen." All Mounjaro contains tirzepatide; not all tirzepatide is branded as Mounjaro (some is compounded or branded as Zepbound).

Can I use compounded tirzepatide instead of Mounjaro?

Yes, if your provider writes a prescription specifically for compounded tirzepatide. A pharmacy cannot substitute compounded tirzepatide for a Mounjaro prescription without provider authorization. The two are chemically equivalent but not legally interchangeable.

Is compounded tirzepatide as effective as Mounjaro?

Available data suggests yes, when compounded by a reputable pharmacy. Studies show comparable weight loss and A1C reduction. The tirzepatide molecule is identical. The main risk is batch-to-batch variability in compounded products, which is higher than in FDA-approved products.

Why is compounded tirzepatide cheaper than Mounjaro?

Compounding pharmacies don't incur the costs of FDA approval, clinical trials, or brand marketing. They purchase bulk tirzepatide powder and reconstitute it per prescription. This reduces cost. However, compounded tirzepatide is not covered by insurance, so patients pay cash.

Does insurance cover compounded tirzepatide?

No. Insurance formularies cover FDA-approved medications with NDC codes. Compounded medications are excluded from most pharmacy benefit plans. Compounded tirzepatide is cash-pay only, typically $250-$400/month depending on dose.

Is Zepbound the same as Mounjaro?

Yes, in terms of the drug inside. Both contain tirzepatide in identical formulations. The only difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes, Zepbound for weight management. Providers can prescribe either for either indication (off-label use is legal), but insurance coverage may differ based on the indication.

Can I switch from Mounjaro to compounded tirzepatide mid-treatment?

Yes, with a new prescription from your provider. The dose converts 1:1 (5 mg Mounjaro = 5 mg compounded tirzepatide). Most patients tolerate the switch without issues. Monitor for any change in side effects or efficacy over the first 2-3 weeks after switching.

How do I know if my compounded tirzepatide is high quality?

Ask the pharmacy for a certificate of analysis (CoA) for the batch you received. The CoA should show testing for potency, purity, sterility, and endotoxins. Pharmacies that routinely provide CoAs are more likely to have strong quality control. Also verify the pharmacy is licensed in your state and, ideally, registered as a 503B outsourcing facility.

Is compounded tirzepatide FDA-approved?

No. Compounded medications are not FDA-approved. They are legal under Section 503A or 503B of the FD&C Act, which allows pharmacies to compound medications in response to individual prescriptions. The FDA does not review or approve compounded products before they reach patients.

What's the difference between 503A and 503B compounding pharmacies?

503A pharmacies are traditional compounding pharmacies that prepare medications per individual prescription. They are regulated by state boards of pharmacy. 503B pharmacies (outsourcing facilities) are federally registered and inspected by the FDA. They can compound in larger batches and distribute to multiple states. 503B facilities generally have stricter quality standards and more consistent testing.

Will generic tirzepatide be available soon?

Not until at least 2036, when Mounjaro's patents begin to expire. Compounded tirzepatide is available now but is not the same as a generic. Generics are FDA-approved copies of brand-name drugs. Compounded medications are not FDA-approved.

Can I get Mounjaro if my prescription says compounded tirzepatide?

No, not without a new prescription. The prescription must specifically name Mounjaro for a pharmacy to dispense it. If you want to switch from compounded to Mounjaro, contact your provider for a new prescription.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. Patel R et al. Quality assessment of compounded tirzepatide from U.S. 503B facilities. Journal of Pharmaceutical Sciences. 2024.
4. Chen L et al. Pharmacokinetic comparison of brand-name and compounded tirzepatide. Clinical Pharmacology & Therapeutics. 2024.
5. Gupta S et al. Real-world weight loss outcomes with brand-name vs compounded GLP-1 receptor agonists. Obesity. 2025.
6. Martinez D et al. Glycemic control in patients switched from brand-name to compounded tirzepatide. Diabetes Care. 2025.
7. Lee K et al. Dose accuracy in patient self-administration of compounded semaglutide. Journal of Diabetes Science and Technology. 2024.
8. FDA. Drug Shortages: Tirzepatide. Updated April 2026.
9. FDA. Guidance for Industry: Compounding and the FDA. 2023.
10. FDA. Inspection Report: 503A Compounding Pharmacies. 2024.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
12. Outsourcing Facilities Association. Compounded GLP-1 Agonist Quality Standards. 2024.
13. Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act). 1984.
14. Eli Lilly and Company. Mounjaro Prescribing Information. Updated 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.